The U.S. Food and Drug Administration (FDA) announced a
change in the evaluation process for certain flu vaccines, stipulating that
some manufacturers must provide stronger evidence of their products' ability to
prevent the disease before receiving marketing authorization.
The measure, implemented during the current administration
of President Donald Trump, represents a shift in the regulatory criteria applied
to certain types of flu vaccines, prioritizing clinical studies that directly
demonstrate their effectiveness in reducing flu cases in the population.
Under the new regulatory approach, pharmaceutical companies
will have to provide additional scientific information supporting the clinical
benefit of their vaccines, thus strengthening the standards required for their
approval and continued availability on the market. Health authorities maintain
that the goal is to bolster public confidence in biological products through
more robust evidence of their performance.
The evolution of this provision will be closely followed by
the pharmaceutical industry, health authorities and the medical community, as
its effects could have repercussions both on regulatory processes and on
strategies for preventing seasonal flu.